Loring Wolcott & Coolidge Fiduciary Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-16	Closed	-$3K	–	852
2021 Q2	$3K	Buy	+16	New	+$2.77K	﹤0.01%	802
2020 Q2	–	Sell	-175	Closed	-$17K	–	617
2020 Q1	$17K	Hold	175	–	–	﹤0.01%	485
2019 Q4	$26K	Hold	175	–	–	﹤0.01%	505
2019 Q3	$22K	Sell	175 -32	-15%	-$4.29K	﹤0.01%	511
2019 Q2	$30K	Buy	207 +32	+18%	+$4.3K	﹤0.01%	463
2019 Q1	$25K	Buy	+175	New	+$22.8K	﹤0.01%	494
2017 Q2	–	Sell	-50	Closed	-$7K	–	645
2017 Q1	$7K	Hold	50	–	–	﹤0.01%	571
2016 Q4	$5K	Hold	50	–	–	﹤0.01%	563
2016 Q3	$6K	Hold	50	–	–	﹤0.01%	571
2016 Q2	$7K	Hold	50	–	–	﹤0.01%	568
2016 Q1	$7K	Hold	50	–	–	﹤0.01%	556
2015 Q4	$7K	Hold	50	–	–	﹤0.01%	582
2015 Q3	$9K	Hold	50	–	–	﹤0.01%	552
2015 Q2	$9K	Hold	50	–	–	﹤0.01%	552
2015 Q1	$9K	Hold	50	–	–	﹤0.01%	567
2014 Q4	$8K	Hold	50	–	–	﹤0.01%	571
2014 Q3	$8K	Hold	50	–	–	﹤0.01%	549
2014 Q2	$7K	Hold	50	–	–	﹤0.01%	575
2014 Q1	$7K	Buy	+50	New	+$7.53K	﹤0.01%	561

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's JAZZ Position: Q3 2021 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 16 shares — an estimated $3K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in JAZZ in Q1 2014 and held it in 19 quarters. The position peaked at $30K in Q2 2019. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 16 Jazz Pharmaceuticals shares in Q3 2021, an estimated $3K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 19 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's Jazz Pharmaceuticals position peaked at $30K in Q2 2019.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.